

priority made in the Declaration submitted with the application filing papers. A "Version with Markings to Show Changes Made" is included herewith.

Applicants have been required under 35 U.S.C. §121 to elect one of Groups I-V.

The restriction states that Applicants are required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-30, drawn to methods of treating and preventing various disorders.

Group II, claim(s) 31-33, 39, 40 drawn to a method for diagnosing a mammal.

Group III, claim(s) 34, 37, 38, 39, 40 drawn to a method for treating a mammalian tumor.

Group IV, claim(s) 35-36, drawn to a method for treating a mammalian tumor.

Group V, claim(s) 41-42, drawn to a method for in vitro detection of a cancer cell in a mammal.

The restriction states that the inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups I-V are drawn to different methods having different goals and method steps. Groups III and IV are distinct because the method set forth in Group IV requires the administration of a cytotoxic agent conjugated to the compound of Formula (I), whereas, Group III does not. The restriction also states that Group II is drawn to an in vivo diagnostic method, whereas Group V is drawn to a distinct in vitro cancer detection method. The restriction also states that Groups I, III and IV do not relate to a single inventive concept because Group I is drawn to a treatment method of various disorders all of which require different steps and have different goals. The

restriction states that Group I does not require the administration of a conjugate as required by Group IV.

The restriction states that the application contains claims directed to more than one species of the generic invention and that these species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The restriction states that the species are as follows: the numerous disorders set forth in claims 1, 3-16, 18, 20-29 and the compounds represented and embraced by Formulas (I) and (II), wherein "Ar", "Arl" and "R3" are as defined in the claims. The restriction requires Applicants to elect a single disorder as well as to elect a single moiety for "Ar", "Arl" and "R3".

The restriction states that the claims are deemed to correspond to the species listed above in the following manner.

The numerous disorders set forth in claims 1, 3-16, 18, 20-29 and the compounds represented and embraced by Formulas (I) and (II), wherein "Ar", "Arl" and "R3" are as defined (claims 1, 2, 18, 19, 30, 31, 32-33, 34, 35, 38, 41).

The restriction states that the following claim(s) are generic: claims 1, 18, 31, 35, 41.

The restriction reasons that the species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the species of disorders (claims 1, 3-16, 18, 20-29) do not relate to a single general inventive concept because they are unrelated disorders and the search for one is not required for the other. The restriction also states that the compounds represented and embraced by Formulas (I) and (II) set forth in

the claims are structurally and chemically distinct and the search for one would not be required for the other.

Pursuant to the request Applicants hereby elect Group I drawn to methods for treating and preventing various disorders (claims 1-30).

The restriction requirement also required an election of species.

Applicants hereby elect sexual dysfunction as the elected disorder.

Applicants hereby elect the following:

Ar- 4-nitrophenyl

Ar1- 1H-Indol-3-yl

R3- 5-methoxy-pyridin-2-yl.

Further, Applicants elect compound 1, page 9, lines 1-2 and claims 17 and 30) i.e. (S) 3-(1H-indol-3-yl)-N-[1-(5-methoxy-pyridin-2-yl)-cyclohexylmethyl]-2-methyl-2-[3-(4-nitro-phenyl)-ureido]-propionamide.

Example-page 12, line 25 to page 14, line 30.

Applicants request an early examination and allowance of the application.

Respectfully submitted,

Date:

11/27/2002



A. Dean Olson
Attorney for Applicant(s)
Reg. No. 31,185

Pfizer Inc.
Patent Department, MS8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-4904

VERSION WITH MARKINGS TO SHOW CHANGES MADE
IN THE SPECIFICATION

Page 1, Please insert, after the Title and before the first line, --This application was filed under
35 U.S.C. §371 based on PCT/GB00/01787 filed May 10, 2000 which claims benefit of U.S.
provisional application serial no. 60/133,355 filed May 10, 1999.--